Compare Ross Stores, Inc. (ROST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Ross Stores, Inc. trades at $222.07 (market cap $71.94B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Ross Stores, Inc. is far larger — about 7.1× State Street SPDR S&P Biotech ETF's market cap, and Ross Stores, Inc. pays a 0.79% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ROST | XBI | |
|---|---|---|
Market Cap | $71.94B | $10.11B |
Volume | 2,002,519 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $255.23 | $169.55 |
52-Week Low | $147.71 | $104.99 |
Typical Hold Time | 48 Days | 38 Days |
Enterprise Value | $72.39B | — |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $222.41, down 1.38% on the day, as technical indicators signal bearish momentum despite strong fundamental performance. The company continues to deliver robust earnings beats with Q2 2026 EPS of $2.66 exceeding expectations of $1.95, while maintaining impressive profitability metrics including 42.63% ROE and 10.85% net income margin. Recent news highlights store expansion initiatives and strong closeout supply positioning the off-price retailer to capture value-conscious consumer demand.
With analyst consensus pointing to 23% upside to the $274.14 price target and 64% buy ratings, ROST presents a compelling growth opportunity despite near-term technical weakness. Key risks include competitive pressures in discount retail and execution challenges in store expansion, but strong cash flow generation and disciplined inventory management support the bullish fundamental case.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
